What should I know first?

Attention-deficit/hyperactivity disorder (ADHD) is a condition of development that can make attention, activity, and impulse control harder to manage. The difficulties are persistent, greater than expected for the child’s age, and interfere with daily life. ADHD can affect learning, friendships, and family routines. A child can have ADHD without being visibly hyperactive. This page focuses on children and teens and on working together with caregivers, schools, and clinicians.

Signs and Symptoms

Inattention may look like frequently losing materials, forgetting instructions, struggling to finish tasks, or having trouble organizing schoolwork. Hyperactivity and impulsivity may include excessive movement, interrupting, or difficulty waiting. Teens may feel restless rather than run or climb constantly. Occasional distraction is common; diagnosis depends on the overall pattern and its impact, not one behavior or a difficult school day.

How Is It Diagnosed?

Start with the child’s pediatrician or another qualified clinician. Assessment brings together developmental and medical history, the child’s perspective, and observations from caregivers and teachers or other adults. Symptoms must have persisted for at least six months, with some present before age 12, and occur in more than one setting with meaningful impairment.

Rating scales help collect information but cannot diagnose ADHD by themselves. There is no single blood test or brain scan for ADHD. The clinician checks for other explanations and coexisting conditions. Bring school reports, examples of difficulties and strengths, sleep information, and a list of medicines or supplements.

How Common Is It?

CDC reports that about 7 million US children ages 3–17, or 11.7%, had a current ADHD diagnosis in the 2024 National Survey of Children’s Health. This estimate comes from parent reports for that population and year. It does not mean that the same proportion applies to every classroom or that a checklist can establish a child’s diagnosis.

What Causes It?

ADHD has a strong genetic contribution and often runs in families. Researchers also study other influences on development; there is no single cause that explains every child’s ADHD. Premature birth and some early exposures are associated with increased risk, but an association cannot explain why a particular child has ADHD. ADHD is not evidence of laziness or failed parenting, and ordinary sugar consumption has not been established as its cause.

What Do We Know About the Brain?

Research examines how brain development relates to attention, planning, and self-control. Findings describe patterns across groups, not a diagnostic picture of one child. A brain scan cannot replace the clinical history and assessment of daily functioning.

Conditions With Similar Symptoms

Poor sleep, anxiety, depression, stress, learning or language difficulties, and hearing or vision problems can resemble ADHD. A child who cannot understand classroom material may also seem distracted. The clinician considers when difficulties began, where they occur, and whether another explanation fits better. Sudden changes deserve assessment rather than an assumption of ADHD.

Other Conditions That Can Occur Together

ADHD can occur with anxiety, depression, learning disabilities, autism, tic disorders, or behavior difficulties. These are separate concerns and may need additional support. Identifying them helps the team choose realistic goals and understand why one treatment may not address every difficulty.

Treatment and Support

Treatment is a partnership between the child, caregivers, healthcare professionals, and teachers. The aim is to make everyday life easier, not simply to make a child quieter or more compliant. Choose a few realistic goals, such as finishing homework with fewer reminders, keeping track of school materials, or taking turns in conversation. Review benefits and side effects regularly and adjust support as the child grows.

Treatment by age

Younger than 6: parent training in behavior management is the first treatment to try, with behavioral classroom support when available. The AAP guideline specifically covers ages 4 through 5; concerns in younger children need individualized developmental assessment. For a 4- or 5-year-old with continuing moderate-to-severe difficulties despite appropriate behavioral treatment, a clinician may consider methylphenidate.

This preschool use is off-label, meaning outside the FDA-approved age indication. When behavioral treatment is unavailable, the clinician weighs medication risks against the harm of delaying care.

Ages 6–11: recommended care combines an FDA-approved ADHD medicine with parent training and/or behavioral classroom interventions, alongside educational support. Choices depend on the child’s needs, health history, response, and family preferences; a recommendation does not mean every child must take medication.

Ages 12–17: medication can be offered with the adolescent’s agreement, together with appropriate behavioral or organizational skills work and school support. Include the teen in choosing goals and discussing benefits, side effects, taking medicine reliably, and pressure to share it.

What behavioral therapy involves

Parent training in behavior management teaches caregivers practical skills to use between sessions. These include clear instructions, consistent expectations and responses, daily routines, and breaking tasks into small steps. Positive reinforcement means encouraging a helpful behavior by following it with a positive consequence, such as specific praise or a reward. For example: “You put your homework in your bag without a reminder—thank you.” Training offers support; it does not mean parents caused ADHD.

Behavioral treatment is active practice, not simply talking to a child about behaving better. Teachers can use clear targets and regular positive feedback in the classroom. Older children and teens may work directly on planning, time management, and organization. Individual psychotherapy, such as cognitive behavioral therapy, can help with coping or co-occurring anxiety or depression; it does not replace parent-focused behavioral treatment for young children.

School support and accommodations

Home and school can agree on short instructions, assignments divided into smaller steps, organizational tools, appropriate movement breaks, fewer distractions, and positive feedback. Regular teacher-caregiver communication helps identify what is working.

A Section 504 plan describes accommodations and related supports that help an eligible student access education. An Individualized Education Program (IEP) is a special education plan for an eligible student who needs specially designed instruction. An ADHD diagnosis does not automatically establish eligibility for either plan. Ask the school for an evaluation; school eligibility and medical diagnosis are separate decisions.

Can Medication Help?

Medication can improve attention and reduce impulsivity and hyperactivity. The right choice depends on age, daily needs, other health conditions, response, and unwanted effects. Read the exact product’s Medication Guide with the prescriber or pharmacist; different release forms and brands are not automatically interchangeable.

Stimulant medicines

Common options include methylphenidate-based medicines and amphetamine-based medicines, such as mixed amphetamine salts. They increase the activity of dopamine and norepinephrine—chemical messengers involved in attention, motivation, and regulation of behavior. The full explanation of their benefit is still being studied. Their purpose is to improve functioning; they do not simply have a calming effect on everyone with ADHD.

Age limits depend on the exact product. FDA’s June 30, 2025 safety communication warns that extended-release stimulants are not approved for children younger than 6 and can cause higher drug exposure, more weight loss, and other side effects in this age group. Extended-release means the medicine is released over a longer period. Ask the prescriber about weight loss or other concerns rather than changing treatment yourself.

Nonstimulant medicines

Nonstimulants may be considered when stimulants do not help enough, cause troublesome effects, or are unsuitable for another reason. FDA-approved pediatric options include atomoxetine and viloxazine extended-release (Qelbree), both for ages 6 and older; guanfacine extended-release (Intuniv), studied and approved for pediatric ADHD ages 6–17; and clonidine extended-release products, including Onyda XR for ages 6 and older. Immediate-release guanfacine and clonidine do not share these ADHD approvals. The exact formulation matters.

Atomoxetine and Qelbree carry boxed warnings—the FDA’s most prominent warning—about suicidal thoughts and behaviors. Watch for new or worsening mood or behavior changes, particularly after starting treatment or changing the dose, and contact the prescriber promptly. Guanfacine and clonidine can cause sleepiness, low blood pressure, and a slow pulse. Do not stop them suddenly: blood pressure can rise sharply. Ask the prescriber what to do if doses are missed or vomiting prevents a dose.

Follow-up and medication safety

Before treatment, share the child’s medical and family history, including heart disease, fainting, and mood symptoms, and a complete list of medicines and supplements. Some combinations must not be used, including stimulants, atomoxetine, or Qelbree with monoamine oxidase inhibitors (MAOIs), a type of antidepressant, or within the required 14-day separation. Serious heart disease and other conditions may rule out particular medicines; product-specific contraindications are explained in the linked medication profiles.

Follow-up checks should cover symptom improvement and daily functioning, appetite, weight, height and growth, sleep, mood, blood pressure and pulse as appropriate for the medicine, side effects, and how consistently doses are taken. Report reduced appetite, weight loss, sleep problems, stomach upset, headaches, unusual sleepiness, or dizziness. These are often manageable, but persistent or troublesome effects need review.

Seek immediate medical care for chest pain, unexplained fainting, or breathing difficulty. New hallucinations—seeing or hearing things others do not—or extreme mood changes need urgent medical advice. Suicidal thoughts need immediate help; call 911 for immediate danger or a life-threatening emergency. Yellow skin or eyes, dark urine, or significant abdominal pain while taking atomoxetine need prompt assessment for possible liver injury.

Stimulants carry boxed warnings about misuse, abuse, and addiction, which can lead to overdose and death. Give only the prescribed medicine and dose, never share it, and keep it securely stored away from children and other people. Diversion means passing a prescribed medicine to someone else. Discuss pressure to share medication with teens and ask the pharmacist about safe disposal.

What to Expect Over Time

ADHD can continue into adult life, although its appearance and the support needed may change. Treatment aims to improve functioning and well-being, not to change a child’s personality. Revisit goals when school demands increase or a teen takes on new responsibilities. Plan follow-up and the eventual transition to adult care rather than assuming that supports are no longer needed.

Everyday Life and Support

Use a predictable schedule, visual reminders, and advance notice of changes. Keep homework supplies in one place, reduce distracting noise, and break longer tasks into short steps with planned breaks. Praise specific effort and progress, set consistent expectations, and let teens choose organizational tools they will actually use.

Regular sleep, enjoyable physical activity, and balanced meals support health and daily functioning. They do not cure ADHD or replace indicated treatment.

When treatment is not helping

Tell the healthcare team what is still difficult and bring examples from home and school. The clinician may revisit the diagnosis and goals, ask about missed doses and side effects, review caregiver and teacher feedback, and check for anxiety, depression, learning difficulties, or sleep problems. The plan may need a different approach or adjustment. Lack of improvement does not mean the child or family has failed.

At the next appointment, ask: Which goal are we tracking? How long should we try this plan? Which side effects should we report, and how urgently? What school support is available? When is our next follow-up?

Supplements and other approaches

Evidence for supplements, herbal remedies, restrictive diets, chiropractic treatment, and other alternative approaches is limited or inconsistent. They have not been shown to cure ADHD. Avoid restrictive diets without professional guidance, particularly when appetite or growth is a concern. Supplements can cause side effects or interact with medicines; discuss them with the child’s healthcare professional before use.

Resources for families

CHADD (Children and Adults with Attention-Deficit/Hyperactivity Disorder) offers ADHD education and family resources. Its National Resource Center on ADHD provides evidence-based information for caregivers, educators, and healthcare professionals. These resources can support conversations with the child’s care team.

Visit CHADD for ADHD education and family resources

History

The names used for ADHD have changed over time. Earlier descriptions focused strongly on activity level and sometimes used terms suggesting brain damage or dysfunction. Those older labels do not show that a particular child has a brain injury. Later terminology gave more attention to difficulties with focus and impulse control, as well as hyperactivity.

Today, ADHD includes inattentive, hyperactive-impulsive, and combined presentations. Pediatric guidance also recognizes that difficulties may continue through adolescence and adulthood. This history helps explain why an older school report or family story may use a different name. A current assessment considers the child’s development, daily functioning, and present needs rather than relying on an old label alone.

Sources and References

AAP and CDC guidance supports the age-based treatment recommendations. FDA safety communications and product labeling support medication information; U.S. Department of Education guidance supports school eligibility information. NIMH and NCCIH provide additional background, and CHADD offers family resources. Source checking is distinct from independent clinical review; no new clinical reviewer endorsement is claimed.

  1. AAP: Attention-Deficit/Hyperactivity Disorder (ADHD)
  2. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of ADHD in Children and Adolescents (2019)
  3. Diagnosing ADHD in Children: Guidelines & Information for Parents
  4. Treatment of ADHD and Related Disorders
  5. Determining ADHD Medication Treatments
  6. Causes of ADHD: What We Know Today
  7. Your Child at School
  8. Treatment of ADHD
  9. Data and Statistics on ADHD
  10. Understanding ADHD: What You Need to Know
  11. Attention-Deficit/Hyperactivity Disorder: What You Need to Know
  12. Parent Training in Behavior Management
  13. ADHD in the Classroom
  14. Resources for Families
  15. FDA: Extended-release stimulants and weight loss risk in children younger than 6 (June 30, 2025)
  16. FDA: Safe use of prescription stimulants—misuse, abuse, addiction, and overdose (May 11, 2023)
  17. Concerta prescribing information (revised February 2026)
  18. Strattera (atomoxetine): current prescribing information
  19. Qelbree (viloxazine extended-release): prescribing information
  20. Intuniv (guanfacine extended-release): prescribing information
  21. Onyda XR (clonidine extended-release): prescribing information
  22. Section 504 Free Appropriate Public Education: Frequently Asked Questions
  23. IDEA regulations: Child with a disability (Section 300.8)
  24. Attention-Deficit Hyperactivity Disorder at a Glance
  25. CHADD: ADHD education and family resources
  26. Frequently Asked Questions about Labeling for Prescription Medicines | FDA
  27. Schizophrenia
  28. NIMH: Understanding psychosis

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top